Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2, 2006. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure Rule 3.1.4R(1)(a). It does not contain general business updates or operational reports.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting specific share transactions by Dr. D. Pulman.
Material Changes
No material changes to the company's financial position or operations are reported. The only changes detailed are personal share transactions by a senior executive:
- Exercise of options on 7,215 Ordinary shares granted in 1997 at GBP 12.75 per share.
- Exercise of options on 130,000 Ordinary shares granted in 2002 at GBP 11.79 per share.
- Sale of 137,215 shares on May 2, 2006, at a price of GBP 15.47 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements regarding the company's performance.
Investor Verification Points
- Verify the total number of shares sold by Dr. D. Pulman (137,215) matches the sum of options exercised (137,215).
- Confirm the sale price of GBP 15.47 per share against the market price on May 2, 2006.
- Note that this filing does not reflect the company's quarterly or annual financial results.